-
Insulin icodec Injection Approved for Marketing by China NMPA
2025-02-19
Recently, the insulin icodec injection (trade name: 诺和期/Awiqli) of Novo Nordisk A/S is approved for marketing by China NMPA.
-
Cofrogliptin Tablets Approved for Marketing by China NMPA
2025-02-19
Recently, the Category 1 innovative drug Cofrogliptin Tablets (trade name: 倍长平) of Haisco Pharmaceutical Group Co., Ltd. is approved for marketing by China NMPA. It is indicated for improving the blood glucose control for adult patients with type 2 diabetes.
-
Golidocitinib Capsules Approved with Conditions for Marketing by China NMPA
2025-02-19
Recently, the Category 1 innovative drug Golidocitinib capsule (trade name:高瑞哲) of Dizal (Jiangsu) Pharmaceuticals Co. Ltd. is approved with condition for marketing through the priority review and approval procedure by China NMPA. This drug is indicated as a single agent for adult patients with relapsed or refractory peripheral T-cell lymphoma (r/r PTCL) who have received at least one line of systemic treatment.
-
Bevifibatide Citrate Injection Approved for Marketing by China NMPA
2025-02-19
Recently, the he Category 1 innovative drug Bevifibatide Citrate Injection (trade name: 贝塔宁/BETAGRIN) of Bio-Thera Solutions, Ltd. is approved for marketing by China NMPA.
-
Fultagliptin Benzoate Tablets Approved for Marketing by China NMPA
2025-02-19
Recently, the Category 1 innovative drug Fultagliptin Benzoate Tablets (trade name: 信立汀) of Shenzhen Salubris Pharmaceuticals Co., Ltd. is approved by China NMPA.
-
Fulzerasib Tablets Approved with Conditions for Marketing by China NMPA
2025-02-19
Recently, the Category 1 innovative drug Fulzerasib Tablets (trade name:达伯特) of Innovent Biologics, Inc. is approved with condition for marketing through the priority review and approval procedure by China NMPA.
